Study Design and Cohort Characteristics of the Childhood Cancer Survivor Study: a Multi-institutional Collaborative Project
Overview
Pediatrics
Authors
Affiliations
Background: Increased attention has been directed toward the long-term health outcomes of survivors of childhood cancer. To facilitate such research, a multi-institutional consortium established the Childhood Cancer Survivor Study (CCSS), a large, diverse, and well-characterized cohort of 5-year survivors of childhood and adolescent cancer.
Procedure: Eligibility for the CCSS cohort included a selected group of cancer diagnoses prior to age 21 years between 1970-1986 and survival for at least 5 years.
Results: A total of 20,276 eligible subjects were identified from the 25 contributing institutions, of whom 15% are considered lost to follow-up. Currently, 14,054 subjects (69.3% of the eligible cohort) have participated by completing a 24-page baseline questionnaire. The distribution of first diagnoses includes leukemia (33%), lymphoma (21%), neuroblastoma (7%), CNS tumor (13%), bone tumor (8%), kidney tumor (9%), and soft-tissue sarcoma (9%). Abstraction of medical records for chemotherapy, radiation therapy, and surgical procedures has been successfully completed for 98% of study participants. Overall, 78% received radiotherapy and 73% chemotherapy.
Conclusion: The CCSS represents the largest and most extensively characterized cohort of childhood and adolescent cancer survivors in North America. It serves as a resource for addressing important issues such as risk of second malignancies, endocrine and reproductive outcome, cardiopulmonary complications, and psychosocial implications, among this unique and ever-growing population.
Mihor A, Martos C, Giusti F, Zadravec-Zaletel L, Tomsic S, Lokar K Cancers (Basel). 2025; 17(4).
PMID: 40002174 PMC: 11853519. DOI: 10.3390/cancers17040580.
Frailty and Sleep in Adult Survivors of Childhood Cancer: A Childhood Cancer Survivor Study Report.
Daniel L, Lubas M, Wang H, Szklo-Coxe M, Ness K, Williams A Psychooncology. 2025; 34(2):e70098.
PMID: 39924630 PMC: 11807945. DOI: 10.1002/pon.70098.
Ghosh T, Hyun G, Dhaduk R, Conces M, Arnold M, Howell R Cancer Med. 2024; 13(20):e70086.
PMID: 39431920 PMC: 11492532. DOI: 10.1002/cam4.70086.
Godoy-Casasbuenas N, Gil F, Arias N, Perez C, Cruz H, Goyes L Ecancermedicalscience. 2024; 18:1759.
PMID: 39430074 PMC: 11489091. DOI: 10.3332/ecancer.2024.1759.
Oster M, Yang Y, Shi C, Anderson S, Knight J, Spector L Am Heart J. 2024; 278:150-160.
PMID: 39299630 PMC: 11806948. DOI: 10.1016/j.ahj.2024.09.003.